Comparison of evaluation system for clinical value of antineoplastic agents at home and abroad
- VernacularTitle:国内外抗肿瘤药物临床价值评估体系比较
- Author:
Yitian LANG
1
;
Qingqing CHAI
1
;
Yahui LIAO
1
;
Xiaoyan LIU
1
;
Yuanjia HU
2
Author Information
1. Dept. of Pharmacy，Huangpu Branch，Shanghai Ninth People’s Hospital，Shanghai Jiaotong University School of Medicine，Shanghai 200011，China
2. State Key Laboratory of Quality Research in Chinese Medicine，University of Macau，Macau 999078，China
- Publication Type:Journal Article
- Keywords:
antineoplastic agents;
clinical value;
value
- From:
China Pharmacy
2022;33(11):1287-1294
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTI VE To introduce the evaluation system for clinical value of antineoplastic agents at home and abroad ，and to provide reference for continuous improvement of clinical value-oriented antineoplastic agents development and research guideline in China. METHODS The suggestions were put forward to improve the evaluation system for clinical value of antineoplastic agents in China by consulting the relevant data of evaluation system for clinical value of antineoplastic agents at home and abroad and domestic antineoplastic agents R&D and management policies ，sort outing and analyzing comparatively their dimensions ， perspectives，target audiences ，application scope ，advantages and disadvantages. RESULTS & CONCLUSIONS Seven foreign value evaluation systems （value assessment framework of American Society of Clinical Oncology ，clinical benefit scale of European Society of Clinical Oncology ，value evaluation framework of American Institute of Clinical and Economic Evaluation ， etc.）had their own characteristics and unique advantages under different settings ；several value evaluation systems differed in the criteria for defining value ，depending on the perspective and population they focus on. The value dimensions were constantly changing dynamically in response to scientific values and social needs ，including not only safety ，efficacy and cost-effectiveness ， but also innovation ，fairness，quality of life attributes. Some evaluation systems adopted value assessment tools that followed the trend of the information age in the presentation form and assessment mode ，which promoted shared decision-making between doctors and patients. Combining the characteristics of foreign value evaluation system and the current situation of development and application of antineoplastic agents in China ，we can have a deeper understanding of drug efficacy ，safety，quality of life ，research and development cost and pricing in the future. Antineoplastic 2021-10-28） agents will have a more reasonable position to solve the unmet needs of patients from the perspectives of drug research and development， clinical application ， drug accessibility and fairness.
